Initiation (new start) criteria: Non-formulary emtricitabine/tenofovir alafenamide (Descovy) will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by immune deficiency clinic (IDC) provider
- AND -
- Diagnosis of human immunodeficiency virus (HIV)
- OR -
- Prescribed for pre-exposure prophylaxis (PrEP)
- AND -
- Patient has failed an adequate trial of emtricitabine/tenofovir disoproxil fumarate (Truvada) or patient has an allergy or intolerance* to emtricitabine/tenofovir disoproxil fumarate (Truvada) unless patient has one of the following:
  - History of osteoporosis or osteopenia
  - Renal impairment defined by two creatinine clearances (CrCl) less than or equal to 70 ml/min or history of chronic renal disease
  - Persistently increased serum creatinine from baseline while using Truvada, defined as 2 or more lab results with an increase of 0.4 mg/dL
  - Sustained proteinuria or glycosuria while using Truvada, defined as 2 or more abnormal lab results
  - Pre-existing condition that increases the patients risk of bone or kidney issues (i.e. older age, diabetes, CKD, etc.)
Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary emtricitabine/tenofovir alafenamide (Descovy) will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by immune deficiency clinic (IDC) provider
  -AND-
- Diagnosis of human immunodeficiency virus (HIV)
  -OR-
- Prescribed for pre-exposure prophylaxis (PrEP)
  -AND-
- Patient has failed an adequate trial^ of emtricitabine/tenofovir disoproxil fumarate (Truvada) or patient has an allergy or intolerance* to emtricitabine/tenofovir disoproxil fumarate (Truvada) unless patient has one of the following:
  - History of osteoporosis or osteopenia
  - Renal impairment defined by two creatinine clearances (CrCl) less than or equal to 70 ml/min or history of chronic renal disease
  - Persistently increased serum creatinine from baseline while using Truvada, defined as 2 or more lab results with an increase of 0.4 mg/dL
  - Sustained proteinuria or glycosuria while using Truvada, defined as 2 or more abnormal lab results
  - Pre-existing condition that increases the patients risk of bone or kidney issues (i.e. older age, diabetes, CKD, etc.)
**Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:** Non-formulary emtricitabine/tenofovir alafenamide (Descovy) will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by immune deficiency clinic (IDC) provider
- **AND**
- Diagnosis of human immunodeficiency virus (HIV)
- **OR**
- Prescribed for pre-exposure prophylaxis (PrEP)
- **AND**
- Patient has failed an adequate trial\(^\text{^\wedge}\) of emtricitabine/tenofovir disoproxil fumarate (Truvada) or patient has an allergy or intolerance\(^*\) to emtricitabine/tenofovir disoproxil fumarate (Truvada) unless patient has one of the following:
  - History of osteoporosis or osteopenia
  - Renal impairment defined by two creatinine clearances (CrCl) less than or equal to 70 ml/min or history of chronic renal disease
  - Persistently increased serum creatinine from baseline while using Truvada, defined as 2 or more lab results with an increase of 0.4 mg/dL
  - Sustained proteinuria or glycosuria while using Truvada, defined as 2 or more abnormal lab results
  - Pre-existing condition that increases the patients risk of bone or kidney issues (i.e. older age, diabetes, CKD, etc.)

---

\(^\text{\wedge}\) Adequate trial is defined as 21-day treatment duration

\(^*\) Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation